Hace1

HACE 1 (HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1) is an ubiquitin ligase with six N-terminal ankyrin and a C-terminal HECT domain. HACE 1 is ubiquitously expressed in normal tissues and is frequently downregulated in human tumors. HACE 1 has been reported to act as a tumor suppressor through a phosphorylation-dependent degradation of cyclin D1. HACE1 has also been shown to bind GTP-bound Rac1 (Ras-related C3 botulinum toxin substrate 1) and to catalyze its polyubiquitination. HACE1 expression increases the ubiquitination of Rac1 when the GTPase is activated. HACE1 is required for cytotoxic necrosis factor 1 (CNSF1)-mediated depletion of Rac1 and efficient invasion of endothelial cell monolayer by bacteria, which suggests a role for HACE1 in host defense against pathogens. More recently, HACE1 was reported to target the Golgi membrane through interactions with Rab proteins. During mitotic Golgi disassembly, the ubiquitin ligase activity of HACE1 is required for subsequent post-mitotic Golgi membrane fusion.

E3 ubiquitin-protein ligase HACE1, HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1, HECT-type E3 ubiquitin transferase HACE1, KIAA1320

Full length human Hace1 recombinant protein

The antibody recognizes the full length HACE 1

8D3

IgG

None

Purified with protein G, stored in PBS pH 7.4 and lyophilized.

If reconstituted with deionized water in 100 µL: WB 1:500, IF 1:500, IHC 1:800. Optimal dilution has to be determined by the user.

Research Use Only

Lyophilized antibodies can be kept at 4ºC for up to 3 months and should be kept at -20ºC for long-term storage (2 years). To avoid freeze-thaw cycles, reconstituted antibodies should be aliquoted before freezing for long-term (1 year) storage (-80ºC) or kept at 4ºC for short-term usage (2 months). For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made with the assay buffer. After the maximum long-term storage period (2 years lyophilized or 1 year reconstituted) antibodies should be tested in your assay with a standard sample to verify if you have noticed any decrease in their efficacy. To limit antibody loss or degradation, BSA (final concentration 1%) and sodium azide (final concentration 0.02%) can be added to the suggested first dilution. It is important to first verify if those preservatives are compatible with your assay.